Cash and cash equivalents

AIM ImmunoTech Reports 2020 Year-End Financial Results

Retrieved on: 
Wednesday, March 31, 2021
AIM ImmunoTech, New York Stock Exchange, Cash and cash equivalents, Rintatolimod, Companies

OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.

Key Points: 
  • OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.
  • As of December 31, 2020, AIM had cash, cash equivalents and marketable securities of $54.4 million, compared with $8.8 million as of December 31, 2019.
  • AIM has been actively engaged in determining whether its drug Ampligen could be an effective treatment for COVID-19.
  • We look forward to updating stockholders and the market as developments unfold, commented Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech.

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 30, 2021
Asset, Cash, Cash and cash equivalents

Cash, Cash Equivalents and Investments Position:As ofDecember 31, 2020, cash, cash equivalents and investments were$74.9 millionas compared with$19.7 millionas ofDecember 31, 2019.

Key Points: 
  • Cash, Cash Equivalents and Investments Position:As ofDecember 31, 2020, cash, cash equivalents and investments were$74.9 millionas compared with$19.7 millionas ofDecember 31, 2019.
  • Research and Development (R&D) Expenses:R&D expenses were$7.8 millionand$28.0 millionfor the quarter and year endedDecember 31, 2020, respectively, as compared with$7.6 millionand$61.5 millionfor the quarter and year endedDecember 31, 2019, respectively.
  • General and Administrative (G&A) Expenses:G&A expenses were$1.0 millionand$9.0 millionfor the quarter and year endedDecember 31, 2020, respectively, as compared with$2.4 millionand$8.7 millionfor the quarter and year endedDecember 31, 2019, respectively.
  • Net Loss:Net loss was$9.9 million and$40.6 millionfor the quarter and year endedDecember 31, 2020, respectively, as compared with$10.0 million and$68.8 millionfor the quarter and year endedDecember 31, 2019, respectively.

Logiq Reports 2020 Revenue up 9.4% to $37.9 Million

Retrieved on: 
Tuesday, March 30, 2021
Revenue, Cash and cash equivalents

Gross profit decreased 25.6% to $1.4 million or 21.1% of revenue in Q4 2020 from $1.9 million or 18.6% of revenue in the same year-ago quarter.

Key Points: 
  • Gross profit decreased 25.6% to $1.4 million or 21.1% of revenue in Q4 2020 from $1.9 million or 18.6% of revenue in the same year-ago quarter.
  • At December 31, 2020, cash and cash equivalents totaled $3.5 million, compared to cash and cash equivalents of $4.8 million at September 30, 2020.
  • Revenue increased 9.4% to $37.9 million in 2020, as compared to $34.6 million in 2019.
  • Gross profit increased 2.0% to $6.4 million or 16.8% of revenue for full year 2020, compared to $6.2 million or 18.0% of revenue in the same year ago period.

Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Retrieved on: 
Monday, March 29, 2021
Periodicals, Economy of New York City, NASDAQ, Decibel, Cash and cash equivalents, Money, Publications

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Key Points: 
  • BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
  • The past nine months have been a strong period of execution for Decibel as we accomplished several key milestones.
  • Fourth Quarter and Full Year 2020 Financial Results:
    Cash Position: As of December 31, 2020, cash, cash equivalents and available-for-sale securities were $54.3 million, compared to $32.3 million as of December 31, 2019.
  • However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Vor Reports Fiscal Year 2020 Financial Results

Retrieved on: 
Thursday, March 25, 2021
Asset, Cash, Cash and cash equivalents, NASDAQ, Money, Finance, Economy

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) (the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today reported financial results for the year ended December 31, 2020, and provided an update on its business.

Key Points: 
  • CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) (the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today reported financial results for the year ended December 31, 2020, and provided an update on its business.
  • We are very pleased with our continued exceptional scientific, clinical and financial progress, noted Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer.
  • Cash and Cash Equivalents: Vor ended 2020 with $48.5 million in cash and cash equivalents, compared with $6.5 million as of December 31, 2019.
  • Net Loss: Vor reported a net loss of $43.3 million for the year ended December 31, 2020, compared with a net loss of $10.8 million for the prior year.

Athersys Announces Financial Results for Fourth Quarter and Full Year 2020

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials, Balance sheet, Asset, Cash, Cash and cash equivalents, BlackBerry Limited, NASDAQ, Companies, Money

Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights.
  • Net loss for the fourth quarter was $22.2 million in 2020 compared to a net loss of $9.9 million in the fourth quarter of 2019.
  • The difference is primarily associated with overall increases in cash usage to fund our clinical development activity in 2020.
  • At December 31, 2020, we had $51.5 million in cash and cash equivalents, compared to $35.0 million at December 31, 2019.

Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 25, 2021
Asset, Cash, Cash and cash equivalents, Economy, Articles

Cash Position: Cash and cash equivalents were $42.4million as of December 31, 2020, as compared to $16.8million as of December 31, 2019.

Key Points: 
  • Cash Position: Cash and cash equivalents were $42.4million as of December 31, 2020, as compared to $16.8million as of December 31, 2019.
  • The increase in cash and cash equivalents was primarily due to Ayalas initial public offering in May 2020.
  • G&A Expenses: General and administrative expenses were $7.4million for the full year 2020, compared to $4.3 million for the same period in 2019.
  • The increase was primarily related to increased costs in connection with becoming a publicly traded company in 2020.

InflaRx Reports Full Year 2020 Financial & Operating Results

Retrieved on: 
Thursday, March 25, 2021
Money, Financial statements, Economy, Asset, Cash, Cash and cash equivalents

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: The year 2020 was a challenging one for all of us dealing with a pandemic.

Key Points: 
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: The year 2020 was a challenging one for all of us dealing with a pandemic.
  • Net financial result decreased by 3.6 million in the year ended December 31, 2020 compared to the year ended December 31, 2019.
  • On December 31, 2020, the Companys total funds available were approximately 81.4million, composed of cash and cash equivalents (26.0million) and financial assets (55.4million).
  • Additional information regarding these results and other relevant information is included in the notes to the financial statements as of December 31, 2020 in ITEM 18.

DGAP-News: Krones AG: Krones expecting increased revenue and profitability in 2021

Retrieved on: 
Thursday, March 25, 2021
Krones, Cash and cash equivalents, Revenue

Krones, the world's leading manufacturer of filling and packaging technology, today published its 2020 Annual Report.

Key Points: 
  • Krones, the world's leading manufacturer of filling and packaging technology, today published its 2020 Annual Report.
  • Net cash and cash equivalents, meaning cash and cash equivalents less bank debt, increased to 184.9 million (previous year: 38.1 million).
  • For financial year 2021, due to ongoing uncertainty about the path of the Covid-19 pandemic, Krones is forecasting revenue growth of 2.5% to 3.5%.
  • This would hit the economy and hence also Krones harder than currently expected and could lead to negative revenue and earnings effects.

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Wednesday, March 24, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Asset, Cash, Cash and cash equivalents

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year for the period ended December 31, 2020.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year for the period ended December 31, 2020.
  • Total net revenues for the fourth quarter 2020 were $219,000, compared to $119,000 for the same period in 2019.
  • Research and development (R&D) expenses for the fourth quarter of 2020 were $1.3 million, compared to $1.7 million in the same period in 2019.
  • Navidea ended the fourth quarter of 2020 with $2.7 million in cash and cash equivalents.